Showing results (351-360 of 391) with videos related to

Sort By:
Pageof 40
Oncology and Therapy|February 13, 2023
Biochemistry-Not Oncogenes-May Demystify and Defeat CancerJay Kulsh
Oncology and Therapy|January 17, 2025
Red Blood Cell Distribution Width May Predict Drug-Induced Anemia and Prognosis in Patients Affected by Primary/Secondary Myelofibrosis Treated with RuxolitinibAlessandro Laganà, Emilia Scalzulli, Ida Carmosino, et al.
Oncology and Therapy|November 5, 2024
Cost-Effectiveness of Pembrolizumab as First-Line Treatment in Patients with Persistent, Recurrent, or Metastatic Cervical Cancer in the United StatesBradley J Monk, Sophie van Mens, Oliver Hale, et al.
Oncology and Therapy|August 10, 2024
Long-Term Temporal Trends of Real-World Healthcare Costs Associated with Nivolumab Plus Ipilimumab and Pembrolizumab Plus Axitinib as First-Line Treatment for Advanced or Metastatic Renal Cell CarcinomaElla Xiaoyan Du, Keith A Betts, Travis Wang, et al.
Oncology and Therapy|July 30, 2024
Treatment Patterns and Resource Use After Osimertinib Discontinuation in Patients with EGFR + Metastatic NSCLCElizabeth Marrett, Winghan Jacqueline Kwong, Jinlin Song, et al.
Oncology and Therapy|July 22, 2024
Dynamic Changes in Circulating Tumor Fraction as a Predictor of Real-World Clinical Outcomes in Solid Tumor Malignancy Patients Treated with ImmunotherapyRyan D Gentzler, John Guittar, Akash Mitra, et al.
Oncology and Therapy|July 4, 2024
Real-World First-Line Maintenance Niraparib Monotherapy Use Following Chemotherapy Plus Bevacizumab: The SW1TCH StudyBobbie Rimel, Tirza Areli Calderón Boyle, Sara Burns, et al.
Oncology and Therapy|September 1, 2024
Causal Relationship Between Gut Microbiota and Leukemia: Future PerspectivesQiang Yang, Zexin Wang, Miao Liu, et al.
Oncology and Therapy|June 5, 2024
Real-World Study of Adjuvant Biosimilar Trastuzumab-dkst for HER2-Positive Breast Cancer Treatment in a Brazilian PopulationDebora Gagliato, Tomás Reinert, Cláudio Rocha, et al.
Oncology and Therapy|May 17, 2024
Gene Therapy for Neurofibromatosis Type 2-Related Schwannomatosis: Recent Progress, Challenges, and Future DirectionsRuofei Yuan, Bo Wang, Ying Wang, et al.
Pageof 40